GlaxoSmithKline Chairman Sir Philip Hampton will step down from his role ahead of the company’s plan to split into two separate business units.
Pfizer snapped up a small percentage of Rhythm Pharmaceuticals, which is focused on treating rare genetic disorders that lead to obesity.
Biopharmaceutical company Celgene Corp. will buy a stake in BeiGene Ltd. and help develop and commercialize BeiGene’s investigational treatment for tumor cancers.
Swiss drugmaker Novartis will invest up to an extra $15 million in Gamida Cell, an Israeli developer of stem cell therapies, Gamida said on Sunday. Novartis last year invested $35 million in the company for a 15 percent stake, in a deal that could reach $600 million if Novartis exercises a buyout option that […]
Transaction underscores Teva’s “personalized-medicine” approach to treatment optimization across a spectrum of specialty and generics development programs and lifecycle management initiatives Teva gains exclusive rights to Immuneering’s cutting-edge analytics to advance treatments for diseases of the CNS JERUSALEM & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and privately-held Immuneering Corporation today […]
Mereo BioPharma Group Ltd (“Mereo”), a recently-formed specialty biopharmaceutical company, announces that it has successfully raised $119m (c. £76.5m), gross, from blue chip institutional investors and simultaneously acquired a portfolio of three innovative clinical-stage development programs from Novartis Pharmaceuticals. Novartis, through the shares issued in consideration for the acquisition of products, will also hold an […]